Literature DB >> 27206387

Estimated prevalence of smallpox vaccine contraindications in Israeli adolescents.

Itay Fogel1, Tal Brosh-Nissimov2, Granit Vager3, Yaron Aviv2, Michael Kassirer2.   

Abstract

BACKGROUND: Routine smallpox vaccination for military recruits was discontinued in Israel in 1996. However, Israeli guidelines recommend post-event mass-vaccination. This study aimed to estimate the rate of Israeli adolescents at risk of severe adverse events after vaccination during 1998-2013.
METHODS: The study population included adolescents screened before military service in 1998-2013. Medical parameters correlating with contraindications to smallpox vaccination were retrieved from army databases, and were categorized by severity according to the Israeli post-event strategy.
RESULTS: Of 1,180,964 individuals, 1.86% had vaccination contraindications in a post-event scenario. An additional 1.24% had contraindications in a pre-event scenario. There was an increase in the percentage of contraindications over time, attributed to the rising incidence of atopic-dermatitis.
CONCLUSIONS: Only a small percentage of the adolescent population is ineligible to receive the smallpox vaccine currently in use. This group may be protected by herd-immunity, or by new-generation vaccines designed to prevent severe adverse events.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bioterrorism; Lister; Modified vaccinia Ankara; Smallpox vaccine; Susceptible population; Vaccinia

Mesh:

Substances:

Year:  2016        PMID: 27206387     DOI: 10.1016/j.vaccine.2016.05.025

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  1 in total

1.  Survey of contraindications in children's routine vaccination in Hangzhou, China.

Authors:  Shijun Liu; Jun Wang; Yan Liu; Yuyang Xu; Xinren Che; Wenwen Gu; Jian Du; Xiaoping Zhang; Erping Xu
Journal:  Hum Vaccin Immunother       Date:  2017-04-13       Impact factor: 3.452

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.